A phase II study of irinotecan combined with S-1 in patients with advanced or recurrent cervical cancer previously treated with platinum based chemotherapy.
Administration, Oral
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Drug Administration Schedule
Drug Combinations
Female
Humans
Irinotecan
/ administration & dosage
Middle Aged
Neoplasm Recurrence, Local
/ drug therapy
Oxonic Acid
/ administration & dosage
Survival Analysis
Tegafur
/ administration & dosage
Treatment Outcome
Uterine Cervical Neoplasms
/ drug therapy
S-1
cervical cancer
chemotherapy
irinotecan
non-platinum doublet
phase II study
Journal
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
ISSN: 1525-1438
Titre abrégé: Int J Gynecol Cancer
Pays: England
ID NLM: 9111626
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
25
08
2018
revised:
25
10
2018
accepted:
02
11
2018
entrez:
6
3
2019
pubmed:
6
3
2019
medline:
23
1
2020
Statut:
ppublish
Résumé
We conducted a phase II study to investigate the efficacy and toxicities of irinotecan plus oral S-1 in patients with advanced or recurrent uterine cervical cancer. Patients with advanced or recurrent cervical cancer previously treated with platinum based chemotherapy were enrolled. Irinotecan (150 mg/m A total of 19 patients were enrolled and treated. The response rate was 29.4%. Grade 3-4 hematologic toxicities were observed in three patients (15.7%). The only grade 3-4 non-hematologic toxicity observed was grade 3 diarrhea. The median progression free survival and overall survival were 3 months and 9 months, respectively. S-1 plus irinotecan in a 3 weekly setting is safe and active in women with advanced or recurrent cervical cancer previously treated with platinum based chemotherapy. Future corroborative clinical studies are warranted.
Identifiants
pubmed: 30833436
pii: ijgc-2018-000070
doi: 10.1136/ijgc-2018-000070
doi:
Substances chimiques
Drug Combinations
0
S 1 (combination)
150863-82-4
Tegafur
1548R74NSZ
Oxonic Acid
5VT6420TIG
Irinotecan
7673326042
Types de publication
Clinical Trial, Phase II
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
474-479Informations de copyright
© IGCS and ESGO 2019. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.